NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and ...

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

GENEVA: The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.